Abstract:BACKGROUND: Esophageal squamous cell carcinoma (ESCC), the predominant type of esophageal cancer, has a 5-year survival rate less than 20%. Although the cause of poor prognosis is the high incidence and mortality of ESCC, the high rate of metastasis after esophageal cancer surgery is the main cause of death after the surgery. Bromodomain-containing protein 4 (BRD4), an epigenetic reader of chromatin-acetylated histones in tumorigenesis and development, plays an essential role in regulating oncogene expression. BRD4 inhibition and BRD4 inhibition-based treatment can potentially suppress ESCC growth. However, the effects and mechanisms of action of BRD4 on ESCC cell migration remain unclear.AIM: To explore the effect of BRD4 on cell migration of ESCC <i>in vitro</i> and its possible molecular mechanism.METHODS: Human ESCC cell lines KYSE-450 and KYSE-150 were used. The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay was performed to examine cell proliferation, and the transwell migration assay was conducted to test ESCC cell migration. JQ1, a BRD4 inhibitor, was applied to cells, and BRD4 siRNA was transfected into ESCC cells to knockdown endogenous BRD4. GFP-RFP-LC3 adenovirus was infected into ESCC cells to evaluate the effect of JQ1 on autophagy. Western blotting was performed to determine the protein levels of BRD4, E-cadherin, vimentin, AMP-activated protein kinase (AMPK), and p-AMPK.RESULTS: BRD4 was either downregulated by small interfering RNA or pretreated with JQ1 in ESCC cells, leading to increased tumor migration in ESCC cells in a dose- and time-dependent manner. Inhibition of BRD4 not only significantly suppressed cell proliferation but also strongly increased cell migration by inducing epithelial-mesenchymal transition (EMT). The protein expression of vimentin was increased and E-cadherin decreased in a dose-dependent manner, subsequently promoting autophagy in KYSE-450 and KYSE-150 cells. Pretreatment with JQ1, a BRD4 inhibitor, inhibited BRD4-induced LC3-II activation and upregulated AMPK phosphorylation in a dose-dependent manner. Additionally, an increased number of autophagosomes and autolysosomes were observed in JQ1-treated ESCC cells. The autophagy inhibitor 3-methyladenine (3-MA) reversed the effects of BRD4 knockdown on ESCC cell migration and blocked JQ1-induced cell migration. 3-MA also downregulated the expression of vimentin and upregulation E-cadherin.CONCLUSION: BRD4 inhibition enhances cell migration by inducing EMT and autophagy in ESCC cells <i>via</i> the AMPK-modified pathway. Thus, the facilitating role on ESCC cell migration should be considered for BRD4 inhibitor clinical application to ESCC patients.

BET Bromodomain Inhibition Potentiates Ocular Melanoma Therapy by Inducing Cell Cycle Arrest

JQ1: a novel potential therapeutic target.

Targeting SIRT1 Synergistically Improves the Antitumor Effect of JQ-1 in Hepatocellular Carcinoma

Combinational Therapeutic Targeting of BRD4 and CDK7 Synergistically Induces Anticancer Effects in Head and Neck Squamous Cell Carcinoma

Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma

The BET inhibitor JQ1 suppresses tumor survival by ABCB5-mediated autophagy in uveal melanoma

Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway

Inhibition of Bromodomain Regulates Cellular Senescence in Pancreatic Adenocarcinoma

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

A 7-Methoxybicoumarin Derivative Selectively Inhibits BRD4 BD2 for Anti-Melanoma Therapy.

Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors

Inhibition of bromodomain-containing protein 4 enhances the migration of esophageal squamous cell carcinoma cells by inducing cell autophagy

The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth Via Regulation of YAP/p21/c-Myc Signaling.

JQ1, a Small Molecule Inhibitor of BRD4, Suppresses Cell Growth and Invasion in Oral Squamous Cell Carcinoma

Enzyme-responsive micellar JQ1 induces enhanced BET protein inhibition and immunotherapy of malignant tumors

Enhanced Efficacy of Histone Deacetylase Inhibitor Combined with Bromodomain Inhibitor in Glioblastoma

The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer

A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products

JQ1 suppresses cell proliferation and induces apoptosis in bladder cancer

Pharmacological Inhibition of Bmi1 by PTC-209 Impaired Tumor Growth in Head Neck Squamous Cell Carcinoma

Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions